NCT02178241 - Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 11, 2014

Primary Completion Date

March 18, 2019

Study Completion Date

July 11, 2019

Conditions

Metastatic Ureter CarcinomaMetastatic Urethral CarcinomaStage III Bladder Urothelial Carcinoma AJCC v6 and v7Stage III Ureter Cancer AJCC v7Stage III Urethral Cancer AJCC v7Stage IV Bladder Urothelial Carcinoma AJCC v7Stage IV Ureter Cancer AJCC v7Stage IV Urethral Cancer AJCC v7Ureter Urothelial CarcinomaUrethral Urothelial Carcinoma

Interventions

DRUG

Eribulin Mesylate

Given IV

DRUG

Gemcitabine Hydrochloride

Given IV

Trial Locations (18)

14263

Roswell Park Cancer Institute, Buffalo

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

20007

MedStar Georgetown University Hospital, Washington D.C.

33612

Moffitt Cancer Center P2C, Tampa

43210

Ohio State University Comprehensive Cancer Center, Columbus

44106

Case Western Reserve University, Cleveland

44195

Cleveland Clinic Foundation, Cleveland

55905

Mayo Clinic Cancer Center P2C, Rochester

60451

UC Comprehensive Cancer Center at Silver Cross, New Lenox

60637

University of Chicago Comprehensive Cancer Center, Chicago

77030

University of Texas M D Anderson Cancer Center P2C, Houston

80045

University of Colorado Hospital, Aurora

90033

Los Angeles County-USC Medical Center, Los Angeles

USC / Norris Comprehensive Cancer Center, Los Angeles

91010

City of Hope Comprehensive Cancer Center, Duarte

91105

Keck Medical Center of USC Pasadena, Pasadena

95817

University of California Davis Comprehensive Cancer Center, Sacramento

M5G 2M9

University Health Network Princess Margaret Cancer Center P2C, Toronto

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH